Management of Idiopathic Recurrent Panniculitis

Diagnostic Confirmation

The American Thoracic Society recommends obtaining a deep excisional biopsy reaching medium-sized vessels and adequate subcutaneous fat tissue to confirm diagnosis, as inadequate depth is the most common diagnostic error 2
Plasma AAT levels should be tested in all cases of biopsy-proven severe panniculitis, particularly with necrotizing or ulcerative features, as AAT deficiency-associated panniculitis requires specific treatment 1, 2
Systemic causes, including polyarteritis nodosa, systemic lupus erythematosus, inflammatory bowel disease, lymphoma, and malignancy, should be ruled out through comprehensive laboratory testing and imaging 2

For patients with confirmed AAT deficiency, the American College of Chest Physicians recommends primary therapy with AAT augmentation using purified human AAT or fresh frozen plasma to restore plasma and tissue levels, which appears rational, safe, and effective 1
The American College of Chest Physicians suggests adding dapsone either alone in less severe cases or combined with augmentation therapy for additional benefit in AAT deficiency-associated panniculitis 1
For truly idiopathic cases after comprehensive workup, moderate-dose oral glucocorticoids (prednisone 0.25-0.5 mg/kg/day) may be used as adjunctive therapy during acute flares, according to the American College of Rheumatology 3

Serial clinical examinations focusing on new nodules, ulcerations, or systemic symptoms are recommended, rather than repeated invasive procedures, by the American College of Rheumatology 3
Immunocompromised patients should continue immunosuppressive therapy for at least 18 months after achieving sustained remission, based on vasculitis management principles, as suggested by the European League Against Rheumatism 4